RxDoctor Payments Data

Amil Shah, MD

Cardiovascular Disease · Dallas, TXNPI 1710976295

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,323 of the $2,451 with a category attached, or 94.8%. Actelion Pharmaceuticals, Ltd accounts for 94.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for cardiovascular disease clinicians in TX, where the typical reported total is $3,258.

$2,451in general payments, 2019–2025

Across 2 payments — averaging $1225.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals, Ltd$2K
  • AbbVie$128
$556,162in research payments, 2019–2025

Across 6 payments — averaging $92,694 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$455K
  • Applied Therapeutics, Inc.$101K

What the payments were for

  • Consulting fees$2,32395%
  • Food & beverage$1285%

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Actelion Pharmaceuticals, Ltd1$2,323
AbbVie1$128

How this compares

$2,451 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$19,557
Medicare patients
284
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →